Harbin Pharmaceutical Group

Harbin Pharmaceutical Group Co., Ltd. (SSE: 600664) is a Chinese partially state-owned pharmaceutical manufacturer.[1][2][3]

Harbin Pharmaceutical Group Co., Ltd.
Simplified Chinese哈药集团股份有限公司
Traditional Chinese哈藥集團股份有限公司
Literal meaningHarbin Pharmaceutical Group, Company Limited by Shares

Business
Harbin Pharmaceutical Group Sixth Pharmaceutical Factory

Harbin Pharmaceutical is engaged in the research, development, manufacture and sale of pharmaceutical products. The Company primarily offers antibiotics, Chinese patent medicines, over-the-counter (OTC) medicines, healthcare products and synthesized preparations, among others.

During the year ended December 31, 2007, the Company obtained approximately 73% and 14% of its total revenue from the sale of western medicines and traditional Chinese medicines, respectively. As of December 31, 2007, the company had two subsidiaries/associates: one specializes in manufacturing oral solutions, while the other is engaged in the retail and wholesale of pharmaceuticals.

References
  1. "Harbin Pharmaceutical to issue RMB 800 mln short-term bonds". news.alibaba.com. 10 November 2008. Retrieved 2020-09-13.
  2. Ferek, Katy Stech (2020-09-10). "Rubio Seeks Security Review of Chinese Bid for GNC". Wall Street Journal. ISSN 0099-9660. Retrieved 2020-09-13.
  3. Stevenson, Alexandra; Kulish, Nicholas; Gelles, David (2020-04-24). "Frantic for Coronavirus Gear, Americans in Need Turn to China's Elite". The New York Times. ISSN 0362-4331. Retrieved 2020-09-13.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.